Cipla Eyes Generic Challenge To Sanofi-Synthelabo's Plavix

Law360, New York (July 26, 2004, 12:00 AM EDT) -- Indian generic drug maker Cipla is planning to apply for approval to sell its version of Sanofi-Synthelabo's Plavix, the blood-thinning drug already at the center of Sanofi’s drawn-out patent litigation against Canada's Apotex and India's Dr. Reddy's.

Sanofi has sued Apotex and Dr. Reddy’s for patent infringement over their plans for generic versions of Plavix in the U.S. District Court for the Southern District of New York in Manhattan.

"Dr Reddy and Apotex have already done it. We won't be the first to request this authorization,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.